Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)

on behalf of the Italian Society of Nephrology (SIN), the Italian Association for the Study of the Liver (AISF), the Italian Society of Infectious and Tropical Disease (SIMIT), the Italian Society of Internal Medicine (SIMI)

Research output: Contribution to journalArticle

Abstract

Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict pathogenetic and prognostic link between HCV infection and CKD requires an ongoing relationship among the healthcare professionals involved in the treatment of both HCV infection and CKD. Therefore, Scientific Societies involved in the care of this high-risk population in Italy have organized a joint expert panel. The aim of the panel is to produce a position statement that can be used in daily clinical practice for the management of HCV infected patients across the whole spectrum of renal disease, from the conservative phase to renal replacement treatments (dialysis and transplantation). Sharing specific evidence-based expertise of different professional healthcare is the first step to obtain a common ground of knowledge on which to instate a model for multidisciplinary management of this high-risk population. Statements cover seven areas including epidemiology of CKD, HCV-induced glomerular damage, HCV-related renal risk, staging of liver disease in patients with CKD, prevention of transmission of HCV in hemodialysis units, treatment of HCV infection and management of HCV in kidney transplantation.

Original languageEnglish
Pages (from-to)1139-1166
JournalInternal and Emergency Medicine
Volume13
Issue number8
DOIs
Publication statusPublished - 2018

Fingerprint

Nephrology
Virus Diseases
Internal Medicine
Chronic Renal Insufficiency
Hepacivirus
Communicable Diseases
Liver
Kidney
Population
Delivery of Health Care
Practice Management
Risk Management
Graft Survival
Proteinuria
Pharmaceutical Preparations
Kidney Transplantation
Italy
Renal Dialysis
Disease Progression
Liver Diseases

Keywords

  • Chronic kidney disease
  • Direct-acting antiviral agents
  • HCV in renal transplantation
  • HCV infection

ASJC Scopus subject areas

  • Internal Medicine
  • Emergency Medicine

Cite this

Management of hepatitis C virus infection in patients with chronic kidney disease : position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). / on behalf of the Italian Society of Nephrology (SIN); the Italian Association for the Study of the Liver (AISF); the Italian Society of Infectious and Tropical Disease (SIMIT); the Italian Society of Internal Medicine (SIMI).

In: Internal and Emergency Medicine, Vol. 13, No. 8, 2018, p. 1139-1166.

Research output: Contribution to journalArticle

on behalf of the Italian Society of Nephrology (SIN), the Italian Association for the Study of the Liver (AISF), the Italian Society of Infectious and Tropical Disease (SIMIT) & the Italian Society of Internal Medicine (SIMI) 2018, 'Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)', Internal and Emergency Medicine, vol. 13, no. 8, pp. 1139-1166. https://doi.org/10.1007/s11739-018-1940-9
on behalf of the Italian Society of Nephrology (SIN) ; the Italian Association for the Study of the Liver (AISF) ; the Italian Society of Infectious and Tropical Disease (SIMIT) ; the Italian Society of Internal Medicine (SIMI). / Management of hepatitis C virus infection in patients with chronic kidney disease : position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). In: Internal and Emergency Medicine. 2018 ; Vol. 13, No. 8. pp. 1139-1166.
@article{7c33165038184cc4a101497c1e2be77f,
title = "Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)",
abstract = "Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict pathogenetic and prognostic link between HCV infection and CKD requires an ongoing relationship among the healthcare professionals involved in the treatment of both HCV infection and CKD. Therefore, Scientific Societies involved in the care of this high-risk population in Italy have organized a joint expert panel. The aim of the panel is to produce a position statement that can be used in daily clinical practice for the management of HCV infected patients across the whole spectrum of renal disease, from the conservative phase to renal replacement treatments (dialysis and transplantation). Sharing specific evidence-based expertise of different professional healthcare is the first step to obtain a common ground of knowledge on which to instate a model for multidisciplinary management of this high-risk population. Statements cover seven areas including epidemiology of CKD, HCV-induced glomerular damage, HCV-related renal risk, staging of liver disease in patients with CKD, prevention of transmission of HCV in hemodialysis units, treatment of HCV infection and management of HCV in kidney transplantation.",
keywords = "Chronic kidney disease, Direct-acting antiviral agents, HCV in renal transplantation, HCV infection",
author = "{on behalf of the Italian Society of Nephrology (SIN)} and {the Italian Association for the Study of the Liver (AISF)} and {the Italian Society of Infectious and Tropical Disease (SIMIT)} and {the Italian Society of Internal Medicine (SIMI)} and Roberto Minutolo and Alessio Aghemo and Antonio Chirianni and Fabrizio Fabrizi and Loreto Gesualdo and Giannini, {Edoardo G.} and Paolo Maggi and Vincenzo Montinaro and Ernesto Paoletti and Marcello Persico and Francesco Perticone and Salvatore Petta and Massimo Puoti and Giovanni Raimondo and Maria Rendina and Zignego, {Anna Linda}",
year = "2018",
doi = "10.1007/s11739-018-1940-9",
language = "English",
volume = "13",
pages = "1139--1166",
journal = "Internal and Emergency Medicine",
issn = "1828-0447",
publisher = "Springer-Verlag Italia s.r.l.",
number = "8",

}

TY - JOUR

T1 - Management of hepatitis C virus infection in patients with chronic kidney disease

T2 - position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)

AU - on behalf of the Italian Society of Nephrology (SIN)

AU - the Italian Association for the Study of the Liver (AISF)

AU - the Italian Society of Infectious and Tropical Disease (SIMIT)

AU - the Italian Society of Internal Medicine (SIMI)

AU - Minutolo, Roberto

AU - Aghemo, Alessio

AU - Chirianni, Antonio

AU - Fabrizi, Fabrizio

AU - Gesualdo, Loreto

AU - Giannini, Edoardo G.

AU - Maggi, Paolo

AU - Montinaro, Vincenzo

AU - Paoletti, Ernesto

AU - Persico, Marcello

AU - Perticone, Francesco

AU - Petta, Salvatore

AU - Puoti, Massimo

AU - Raimondo, Giovanni

AU - Rendina, Maria

AU - Zignego, Anna Linda

PY - 2018

Y1 - 2018

N2 - Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict pathogenetic and prognostic link between HCV infection and CKD requires an ongoing relationship among the healthcare professionals involved in the treatment of both HCV infection and CKD. Therefore, Scientific Societies involved in the care of this high-risk population in Italy have organized a joint expert panel. The aim of the panel is to produce a position statement that can be used in daily clinical practice for the management of HCV infected patients across the whole spectrum of renal disease, from the conservative phase to renal replacement treatments (dialysis and transplantation). Sharing specific evidence-based expertise of different professional healthcare is the first step to obtain a common ground of knowledge on which to instate a model for multidisciplinary management of this high-risk population. Statements cover seven areas including epidemiology of CKD, HCV-induced glomerular damage, HCV-related renal risk, staging of liver disease in patients with CKD, prevention of transmission of HCV in hemodialysis units, treatment of HCV infection and management of HCV in kidney transplantation.

AB - Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict pathogenetic and prognostic link between HCV infection and CKD requires an ongoing relationship among the healthcare professionals involved in the treatment of both HCV infection and CKD. Therefore, Scientific Societies involved in the care of this high-risk population in Italy have organized a joint expert panel. The aim of the panel is to produce a position statement that can be used in daily clinical practice for the management of HCV infected patients across the whole spectrum of renal disease, from the conservative phase to renal replacement treatments (dialysis and transplantation). Sharing specific evidence-based expertise of different professional healthcare is the first step to obtain a common ground of knowledge on which to instate a model for multidisciplinary management of this high-risk population. Statements cover seven areas including epidemiology of CKD, HCV-induced glomerular damage, HCV-related renal risk, staging of liver disease in patients with CKD, prevention of transmission of HCV in hemodialysis units, treatment of HCV infection and management of HCV in kidney transplantation.

KW - Chronic kidney disease

KW - Direct-acting antiviral agents

KW - HCV in renal transplantation

KW - HCV infection

UR - http://www.scopus.com/inward/record.url?scp=85053910540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053910540&partnerID=8YFLogxK

U2 - 10.1007/s11739-018-1940-9

DO - 10.1007/s11739-018-1940-9

M3 - Article

AN - SCOPUS:85053910540

VL - 13

SP - 1139

EP - 1166

JO - Internal and Emergency Medicine

JF - Internal and Emergency Medicine

SN - 1828-0447

IS - 8

ER -